Updates on Oral COVID Therapy

Nirmatrelvir-Ritonavir continues to be recommended for outpatient treatment of COVID-19 infections, especially as cases continue to rise. However, this therapy does present clinical challenges – from drug interactions to off-label dosing and rebound COVID-19 infections, therapy is not as easy as it sounds. Listen as host Geoff Wall describes the clinical challenges and guest Jake Galdo describes the public health considerations for nirmatrelvir-ritonavir use.The GameChanger Nirmatrelvir-ritonavir has significant clinical challenges including various drug interactions with DOACs, statins, amiodarone, and tacrolimus, for example. It’s also important to note that COVID-19 rebound after nirmatrelvir-ritonavir is not due to resistance based on the latest data.Show Segments 00:00 – Introductions 01:25 – Nirmatrelvir-Ritonavir Updates 04:27 – Nirmatrelvir-Ritonavir Controversy  06:30 – Drug Interactions  08:05 – DOACs and Nirmatrelvir-Ritonavir  11:44 – Statin and Nirmatrelvir-Ritonavir 13:04 – Amiodarone and Nirmatrelvir-Ritonavir 15:02 – Tacrolimus and Nirmatrelvir-Ritonavir  19:33 – COVID-19 Rebound  23:38 – Equity and Access 31:44 – Closing Remarks Host Geoff Wall, PharmD, BCPS, FCCP, CGP Professor of Pharmacy Practice, Drake University Internal Medicine/Critical Care, UnityPoint Health GuestJohn A. Galdo, PharmD, MBA, BCPS, BCGP (Jake)Course Content and Developer, CEimpactPharmacist, Ross Bridge PharmacyCEO, Seguridad, IncDr. Galdo have no relevant financial relationships to disclose. References and ResourcesUniversity of Liverpool Drug Interactions CDC Health Advisory on COVID Rebound InfectionsPaxlovid Patient Eligibility Screening Checklist Tool for PrescriberRedeem your CPE or CME creditCPE (Pharmacist) CME (Physician) Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode) Pharmacists: Get a MembershipPrescribers: Get a Membership  Continuing Education InformationLearning Objectives:1. Explain common drug interactions associated with Nirmatrelvir-Ritonavir2. Discuss COVID ‘rebound’ infections3. Describe public health and healthcare data considerations for Nirmatrelvir-Ritonavir use 0.05 CEU | 0.5 HrsACPE UAN: 0107-0000-22-247-H01-PInitial release date: 07/11/22Expiration date: 07/11/2023Additional CPE & CME details can be found hereFollow CEimpact on Social Media:LinkedInInstagram